CORNERSTONE: A ProspeCtive ObseRvatioNal Study of Atogepant Effectiveness in Routine Clinical Practice
Summary
To evaluate patient-reported improvement with atogepant for the prevention of
migraine in the real-world setting.
Eligibility
Eligible ages: 18 to 100
Accepts healthy participants: Yes
Inclusion criteria:
1. Patients who are able to give voluntary informed consent.
2. Adult patients who are aged ≥18 at the time of informed consent.
3. Patients who have at least 1-year history of migraine with or without aura consistent with a diagnosis.
4. Patients prescribed atogepant.
5. For patients who initiate atogepant at the prescribing physician or treating healthcare practitioner discretion, the decision to administer atogepant must be made prior to and independent of recruitment into the study.
6. Patients who are willing and able to comply with the requirements of the study.
7. Patients who are not currently on a preventive medication for migraine, or have been on a stable preventive medication for migraine for at least 3 months prior to enrollment in the study. If on a stable preventive medication, the prescribing physician or treating healthcare practitioner and patient must confirm that there is no plan to change concomitant preventive medication during the first 12 weeks of the study.
Exclusion criteria:
1. Patients who were previously exposed to atogepant as routine therapy or from
clinical trials experience prior to entry.
2. Patients who have any contraindications to atogepant.
3. Patients who are pregnant or planning to be pregnant or women of childbearing
potential not using contraception.
4. Patients who are enrolled in any interventional studies that may include
investigational compounds for migraine, or non-AbbVie observational studies.
5. In the opinion of the prescribing physician or treating healthcare provider, the patient has a history or current evidence of any condition that might interfere with patient's ability to comply with the study requirements.
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
CHAMP (Calgary Headache Assessment & Management Program) Research Office Outpatient Neurology, 5th Floor Clinic 5E South Health Campus
Principal investigator:
Farnaz Amoozegar
Clinical trial:
Yes
REB-ID:
REB24-1335